Drugs / CLS-TA
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02949024 | Nov 2016 → Oct 2017 | diabetic macular edema | Clearside Biomedical, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02980874 | Jan 2017 → Dec 2018 | macular retinal edema, retinal vein occlusion | Clearside Biomedical, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02595398 | Nov 2015 → Jan 2018 | anterior uveitis, intermediate uveitis, panuveitis, posterior uveitis | Clearside Biomedical, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03126786 Comparator | Jul 2017 → Apr 2018 | diabetic macular edema | Clearside Biomedical, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03203447 Comparator | Mar → Dec 2018 | macular retinal edema, retinal vein occlusion | Clearside Biomedical, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLS-TA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02949024 ↗ |
| Route | Other | “4 mg of CLS-TA administered via suprachoroidal injection” NCT02595398 ↗ |